A Guide to Custom VHH Discovery Service for Veterinary Diagnostic Development

A custom VHH discovery service helps diagnostic developers identify single-domain antibody binders against a selected target and evaluate whether they may be suitable for an assay. For veterinary diagnostics, the work should be designed around the intended animal species, sample type, assay format, and relevant sources of cross-reactivity—not just binding to a purified antigen. At NBbiolab, we recommend defining these requirements before requesting a proposal so the discovery plan and deliverables can be matched to the intended test.

You can find more information on our web, so please take a look.

This guide explains the main development stages, material options, buyer decision points, and questions to ask a potential supplier. It also clarifies what to confirm about cost, minimum order requirements, and lead time, which depend on project scope and should be quoted rather than assumed.

Key Takeaways

• Start with the diagnostic use case: target, animal species, sample matrix, assay format, and intended workflow.
• Assess candidates for assay-relevant performance, including specificity and function in the intended format, not binding alone.
• Agree in advance on project stages, deliverables, evaluation criteria, and any rights or material-transfer conditions.
• Pricing, minimum quantities, and timelines vary with the target, discovery approach, validation scope, and requested formats.

Who This Guide Is For

This guide is for veterinary diagnostic manufacturers, assay developers, animal-health biotechnology companies, and research teams considering custom binders for a new or improved test. It is relevant whether you are developing a laboratory immunoassay, a lateral-flow test, or another antibody-based format. The right discovery plan depends on the intended product and does not guarantee that a candidate will meet final diagnostic performance requirements.

What a Custom VHH Discovery Service Involves

VHHs are single-domain antibody fragments derived from the variable region of heavy-chain-only antibodies found in camelids. A typical VHH is approximately 12–15 kDa, though the exact mass depends on its sequence and any attached components. Its compact, single-domain format can be useful in some assay designs, but suitability must be demonstrated for each target and application.

A custom discovery project generally aims to identify and characterize candidate VHHs against a customer-defined antigen or target. Depending on the supplier’s platform and the agreed scope, work may include target review, immunization or library-based discovery, screening, sequence identification, expression, and initial characterization. These are potential project elements, not a fixed package; confirm which activities and outputs are included in the proposal.

Common Material and Output Options

Early-stage projects may produce sequence information, expressed VHH candidates, or both. Later work may include reformatting, such as adding a tag or combining binders for a particular assay architecture, and preparation of material for evaluation. A VHH domain is often around 110–130 amino acids, but sequence length and construct design vary; ask the supplier to specify the exact construct and format.

Consider whether you need a screening-stage candidate, purified protein for assay development, or additional support with optimization. These are different scopes and should not be treated as interchangeable deliverables. Confirm expression host, purification method, quantity, concentration, buffer, and documentation before placing an order.

Match the Discovery Plan to the Veterinary Application

The target and assay context influence how candidates should be screened. For a serological test, the relevant target may be an antibody in the animal’s sample rather than a pathogen antigen; for an antigen-detection test, the binder may need to recognize a pathogen-associated protein in a biological matrix. Be specific about the intended species and specimen, such as serum, plasma, milk, or a swab-derived sample.

Veterinary assays may be used across different species, breeds, age groups, or disease stages. Where the intended product spans more than one species, define that requirement early and ask how it will be evaluated. A binder that recognizes a purified target may still behave differently in a complex sample or in a different assay format.

Assay-Relevant Evaluation

Ask how the supplier will distinguish binding from useful assay performance. Depending on the project, evaluation may consider target specificity, binding signal, background, reproducibility, and compatibility with the planned detection method. For tests involving related organisms or host proteins, discuss the cross-reactivity panel and the available reference materials before screening begins.

With competitive price and timely delivery, NBbiolab sincerely hope to be your supplier and partner.

Set measurable acceptance criteria with the supplier, but avoid adopting generic thresholds without considering the product’s intended use. A laboratory assay and a field-oriented rapid test may have different constraints for sensitivity, workflow, sample preparation, and operating conditions. If stability is important, agree on study conditions and duration; for example, a development plan could compare storage at 2–8°C and 20–25°C, without assuming those conditions alone establish shelf life.

A Practical Selection Framework

1. Define the Diagnostic Goal

Write down the analyte, target species, sample type, test format, and intended user. Clarify whether the VHH is a capture reagent, a detection reagent, or part of a pair. Include constraints such as available sample volume, required turnaround, and whether the assay is intended for laboratory or near-patient use.

2. Review the Target and Reagents

Provide the target’s sequence or identity, source, construct details, and any known variants or related proteins. Tell the supplier whether the available antigen is recombinant, purified from a source material, or presented in another form. Where possible, discuss whether the screening antigen reflects the form encountered in the diagnostic sample.

3. Agree on the Discovery and Screening Plan

Ask which discovery approach is proposed and why it fits your target. Confirm the planned screening stages, controls, candidate selection criteria, and whether screening will use the intended assay format or only an initial binding assay. If the final test uses a particular label, surface, or sample matrix, establish when and how compatibility will be assessed.

4. Confirm Deliverables and Rights

Specify whether the final package includes sequences, expressed material, purification details, characterization data, and any follow-up optimization. Clarify ownership, permitted use, confidentiality, and conditions for transferring materials or data. These points can affect how readily a candidate moves from discovery into product development.

Pricing, Minimum Orders, and Lead Time

Custom discovery pricing is project-specific. Key factors can include target complexity, discovery method, number of candidates requested, screening depth, expression and purification, and additional assay or stability work. A quote should identify included stages, optional work, material quantities, and any fees associated with repeat or follow-on experiments.

Minimum order quantities may differ for discovery services, purified research material, and later production. Lead time also depends on project design, target readiness, reagent availability, and the number of evaluation stages. Request an estimated schedule with milestones and dependencies rather than relying on a general turnaround figure that may not apply to your project.

Supplier Evaluation Checklist

• Can the supplier explain how the proposed workflow fits your target and veterinary assay format?
• Are screening methods, controls, and candidate-selection criteria described clearly?
• Will evaluation address relevant species, sample matrices, and likely cross-reactivity concerns?
• Are sequence, protein, characterization, and documentation deliverables explicitly listed?
• Are ownership, confidentiality, usage rights, pricing assumptions, and project dependencies clear?
• Can the supplier describe what happens if initial candidates do not meet agreed criteria?

Look for specific answers rather than broad promises of performance. A responsible supplier should distinguish exploratory screening results from validation of a finished diagnostic product. Ask which experiments are included and which would require a separate scope.

How NBbiolab Can Support Your Project

At NBbiolab, we can discuss your veterinary diagnostic objective, target information, preferred assay format, and expected development outputs to help determine whether a custom VHH discovery project is appropriate. Sharing these details at the inquiry stage can make it easier to scope candidate discovery, assay-relevant evaluation, and material requirements. Any proposed activities, schedule, and deliverables should be confirmed in a project-specific quotation.

Conclusion: Choose for the Intended Assay, Not Binding Alone

A custom VHH discovery service can provide candidate binders for veterinary diagnostic development, but the useful candidate is the one that fits the intended target, species, sample matrix, and assay workflow. Before engaging a supplier, define the use case, agree on screening and acceptance criteria, and confirm deliverables, rights, cost assumptions, and schedule. The next step is to prepare a short project brief with your target details and assay requirements, then discuss feasibility and scope with NBbiolab.